Stock NAMS FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Frazier Lifesciences Acquisition Corporation Stock

Equities

NAMS

NL00150012L7

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-04-11 pm EDT 		5-day change 1st Jan Change
19.7 EUR -1.15% Intraday chart for Frazier Lifesciences Acquisition Corporation +0.46% +76.37%
Apr. 09 NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease CI
Apr. 01 NewAmsterdam Pharma Names Juliette Audet Chief Business Officer MT

Financials

Sales 2024 * 9.83M 10.44M Sales 2025 * 7.75M 8.23M Capitalization 1.66B 1.76B
Net income 2024 * -163M -173M Net income 2025 * -128M -136M EV / Sales 2024 * 169 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 214 x
P/E ratio 2024 *
-10.4 x
P/E ratio 2025 *
-13.7 x
Employees 29
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.23%
More Fundamentals * Assessed data

Chart Frazier Lifesciences Acquisition Corporation

Dynamic Chart

Latest news about Frazier Lifesciences Acquisition Corporation

NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease CI
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer MT
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer CI
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target MT
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd CI
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk MT
NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops MT
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NewAmsterdam Pharma Prices $175.3 Million Public Offering MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target MT
NewAmsterdam Pharma Company N.V. Announces Board Changes CI
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target MT
NewAmsterdam Pharma Appoints Ian Somaiya as Chief Financial Officer MT
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer CI
More news

Analyst Recommendations on Frazier Lifesciences Acquisition Corporation

Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target MT
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target MT
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target MT
Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating MT
More recommendations

Press releases Frazier Lifesciences Acquisition Corporation

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer AQ
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress GL
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD GL
More press releases

Quotes and Performance

1 day-1.15%
1 week+0.46%
Current month-16.70%
1 month-10.58%
3 months+12.38%
6 months+171.72%
Current year+76.37%
More quotes

Highs and lows

1 week
18.22
Extreme 18.22
20.21
1 month
18.22
Extreme 18.22
24.79
Current year
11.18
Extreme 11.18
26.35
1 year
5.63
Extreme 5.6326
26.35
3 years
5.63
Extreme 5.6326
32.88
5 years
5.63
Extreme 5.6326
32.88
10 years
5.63
Extreme 5.6326
32.88
More quotes

Quotes

Date Price Change Volume
24-04-15 19.74 +0.20% 268,390
24-04-12 19.7 -1.15% 40,992
24-04-11 19.93 +4.35% 56,058
24-04-10 19.1 +0.79% 260,844
24-04-09 18.95 -3.37% 435,259

End-of-day quote Nasdaq, April 11, 2024

More quotes

Company Profile

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer's disease. The Company strives to offer its products around the world.
Sector
Biotechnology & Medical Research
Calendar
2024-05-05 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Frazier Lifesciences Acquisition Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
18.57 EUR
Average target price
30.79 EUR
Spread / Average Target
+65.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
FRAZIER LIFESCIENCES ACQUISITION CORPORATION Stock Frazier Lifesciences Acquisition Corporation
+76.37% 1.76B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.13% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.80% 96.56B
ARGENX SE Stock argenx SE
+1.72% 22.61B
BIONTECH SE Stock BioNTech SE
-18.19% 21.18B
GENMAB A/S Stock Genmab A/S
-4.50% 19.07B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.75% 16.53B
BEIGENE, LTD. Stock BeiGene, Ltd.
-25.68% 14.46B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.93% 13.25B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.63% 11.1B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NAMS Stock